Resumen de acción HIK
Hikma Pharmaceuticals PLC desarrolla, fabrica, comercializa y vende una gama de productos farmacéuticos genéricos, de marca y con licencia.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Competidores de Hikma Pharmaceuticals PLC
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | UK£19.24 |
| 52 Week High | UK£22.22 |
| 52 Week Low | UK£17.11 |
| Beta | 0.44 |
| 1 Month Change | 0.29% |
| 3 Month Change | 0.65% |
| 1 Year Change | 4.40% |
| 3 Year Change | -17.67% |
| 5 Year Change | 8.55% |
| Change since IPO | 582.27% |
Noticias y actualizaciones recientes
Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24
Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Recent updates
Is Hikma Pharmaceuticals PLC (LON:HIK) Trading At A 29% Discount?
Apr 24Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Apr 02Hikma Pharmaceuticals PLC's (LON:HIK) Share Price Matching Investor Opinion
Feb 25Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Dec 27An Intrinsic Calculation For Hikma Pharmaceuticals PLC (LON:HIK) Suggests It's 43% Undervalued
Dec 12Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Sep 19Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Sep 01Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Jun 21Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 28% Above Its Share Price
Jun 02Hikma Pharmaceuticals (LON:HIK) Has A Pretty Healthy Balance Sheet
Mar 14Calculating The Intrinsic Value Of Hikma Pharmaceuticals PLC (LON:HIK)
Feb 21Does Hikma Pharmaceuticals (LON:HIK) Have A Healthy Balance Sheet?
Sep 27Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 19% Below Its Share Price
Jun 24These 4 Measures Indicate That Hikma Pharmaceuticals (LON:HIK) Is Using Debt Reasonably Well
Jun 06Here's Why Hikma Pharmaceuticals (LON:HIK) Can Manage Its Debt Responsibly
Feb 26Hikma Pharmaceuticals PLC's (LON:HIK) Intrinsic Value Is Potentially 92% Above Its Share Price
Dec 01Is Hikma Pharmaceuticals (LON:HIK) Using Too Much Debt?
Nov 11Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 32% Undervaluation?
Sep 02Is Hikma Pharmaceuticals (LON:HIK) A Risky Investment?
Aug 09Hikma Pharmaceuticals PLC (LON:HIK) Shares Could Be 26% Below Their Intrinsic Value Estimate
May 21Hikma Pharmaceuticals (LON:HIK) Seems To Use Debt Quite Sensibly
May 03It's Unlikely That Hikma Pharmaceuticals PLC's (LON:HIK) CEO Will See A Huge Pay Rise This Year
Apr 16How Does Hikma Pharmaceuticals PLC (LON:HIK) Stand Up To These Simple Dividend Safety Checks?
Apr 13Hikma Pharmaceuticals PLC (LON:HIK) Looks Interesting, And It's About To Pay A Dividend
Mar 14Hikma Pharmaceuticals PLC Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Feb 28I Ran A Stock Scan For Earnings Growth And Hikma Pharmaceuticals (LON:HIK) Passed With Ease
Feb 22Is There An Opportunity With Hikma Pharmaceuticals PLC's (LON:HIK) 23% Undervaluation?
Feb 03Rentabilidad de los accionistas
| HIK | GB Pharmaceuticals | Mercado GB | |
|---|---|---|---|
| 7D | 6.1% | 5.4% | 1.2% |
| 1Y | 4.4% | 5.4% | 2.3% |
Rentabilidad vs. Industria: Los resultados de HIK fueron inferiores a los de la industria UK Pharmaceuticals, que obtuvo un rendimiento del 5.4% el año pasado.
Rentabilidad vs. Mercado: HIK superó al mercado UK, que obtuvo un rendimiento del 0.9% el año pasado.
Volatilidad de los precios
| HIK volatility | |
|---|---|
| HIK Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 8.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Precio estable de las acciones: HIK no ha tenido una volatilidad de precios significativa en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de HIK (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1978 | 9,100 | Riad Mishlawi | www.hikma.com |
Hikma Pharmaceuticals PLC desarrolla, fabrica, comercializa y vende una gama de productos farmacéuticos genéricos, de marca y bajo licencia. Opera a través de tres segmentos: Inyectables, Genéricos y de Marca. El segmento de inyectables suministra productos genéricos inyectables principalmente para su uso en hospitales.
Resumen de fundamentos de Hikma Pharmaceuticals PLC
| Estadísticas fundamentales de HIK | |
|---|---|
| Capitalización bursátil | UK£4.27b |
| Beneficios(TTM) | UK£152.18m |
| Ingresos (TTM) | UK£2.30b |
28.1x
Ratio precio-beneficio (PE)1.9x
Ratio precio-ventas (PS)¿Está HIK sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de HIK | |
|---|---|
| Ingresos | US$2.88b |
| Coste de los ingresos | US$1.47b |
| Beneficio bruto | US$1.41b |
| Otros gastos | US$1.22b |
| Beneficios | US$190.00m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
Aug 08, 2024
| Beneficios por acción (BPA) | 0.86 |
| Margen bruto | 48.94% |
| Margen de beneficio neto | 6.61% |
| Ratio deuda/patrimonio | 50.9% |
¿Cómo se ha desempeñado HIK a largo plazo?
Ver rendimiento histórico y comparativa